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ABSTRACT
Objective The aim of this study was to estimate the 
proportion of rubella disease in a measles case-based 
surveillance in Cameroon prior to rubella vaccine 
introduction into the national immunisation programme.
Design This was a cross-sectional study for rubella 
infection in Cameroon for the period 2008 to 2014.
Setting Patients suspected with measles from the 10 
regions of Cameroon were recruited according to the WHO 
measles case definition and were tested for rubella IgM 
antibodies accompanied with the case report/investigation 
forms.
Participants All persons with rash and fever within 14 
days of onset of rash according to the standard WHO 
African Regional Office (WHO/AFRO) case definition for a 
suspected measles case.
Outcome measures Descriptive analyses and simple 
logistic regressions were performed. OR were estimated.
Results A total of 9907 serum samples from people 
with fever and rash were received in the laboratory from 
2008 to 2014. A total of 7489 (75.59%) measles-negative 
samples were tested for rubella; 699 (9.3%) were positive 
for rubella IgM antibodies. Logistic regression analysis 
was done using IgM antibodies detection as the outcome 
variable. Age, sex and setting were explanatory variables. 
Logistic regression analysis revealed that, comparing 
the proportion of rubella IgM seropositivity status by age, 
the association to a positive rubella IgM increased with 
age from 1 to 4 years (OR 7.11; 95% CI 4.35 to 12.41; 
p<0.0001), through 5 to 9 years (OR 13.07; 95% CI 
7.93 to 22.93; p<0.001), to 10 to 14 years of age (OR 
13.86; 95% CI 8.06 to 25.12; p<0.001). Persons aged 
≥15 years were also more likely to have rubella infection 
than children under one (OR 3.69; 95% CI 1.85 to 7.48; 
p=0.0001). There were also significant associations 
with sex, with males being less associated to a positive 
rubella serology than females (OR 1.33; 95% CI 1.14 to 
1.56; p=0.0001). No statistically significant difference in 
proportion of rubella cases was observed between urban 
and rural populations (OR 1.11; 95% CI 0.94 to 1.31; 
p=0.208).
Conclusions This study reveals that rubella virus 
circulates in Cameroon, with important number of cases in 
children under 15 years. This finding supports the planned 
introduction of rubella-containing vaccines into the 
Expanded Program on Immunization.
INTRODUCTION
Rubella is an acute, contagious viral disease 
caused by a Togavirus of the genus Rubivirus 
and is characterised by a mild maculopapular 
rash.1 The illness is often mild in children but 
has serious consequences in pregnant women. 
Arthralgia or arthritis may occur in up to 70% 
of adult women infected with rubella with rare 
complications including thrombocytopenic 
purpura and encephalitis.2 3 The infection 
in women during the first trimester of preg-
nancy can severely affect the fetus, resulting 
in miscarriage, fetal death or the combi-
nation of disabling conditions collectively 
called congenital rubella syndrome (CRS). 
Common birth defects are ocular (retinitis, 
microphthalmia, glaucoma and cataracts), 
hearing impairment, hearing defects, pulmo-
nary stenosis, persistent ductus arteriosus, 
microcephaly, developmental delay, mental 
retardation, bone alterations and damage 
to the liver and spleen.4 Global estimates of 
the burden of rubella suggest that 100 000 
infants are born with CRS each year which 
makes rubella a leading cause of preventable 
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Strengths and limitations of this study
 ► This is the first study in Cameroon to investigate 
rubella infection across a broad age range, from all 
the regions and investigating association with some 
sociodemographic factors.
 ► The integration of rubella testing with measles case-
based surveillance provides an opportunity to gain 
understanding about the epidemiology of rubella 
infection.
 ► The sensitivity of the case definition used for 
measles surveillance is likely not high enough to 
identify all rubella cases.
 ► The existence of missing data for some variables 
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congenital defects.5 6 The estimates for 2008 suggest that 
the highest CRS burden is in South-East Asia (48%) and 
Africa (38%). Economic analysis for rubella and CRS 
control suggest that incorporation of rubella-containing 
vaccine (RCV) into national childhood immunisation 
schedules is both cost-beneficial and cost-effective.7 Esti-
mates suggest a wide range for the lifetime cost of treating 
a single CRS case from US$4200 (inflation-adjusted 
2012), in a middle-income country such as Brazil, to 
over US$200 000 (inflation-adjusted 2012), in a high-in-
come country such as the USA.8 At least five of six WHO 
regions have set rubella control or elimination targets by 
the year 2020, since the Measles and Rubella Initiative was 
launched in 2001.7
In Cameroon, the national Expanded Program on 
Immunization (EPI) was established in 1976 and includes 
provision of the first dose of measles-containing vaccine 
(MCV1) at 9 months of age. Measles case-based surveil-
lance has been integrated to the acute flaccid paralysis 
surveillance system to monitor the progress with measles 
control. Rubella vaccination has not yet been introduced 
into the infant vaccination schedule in Cameroon, and 
furthermore, surveillance of rubella per se or CRS does 
not exist. However, the measles case-based surveillance 
system, established in 2004, includes laboratory testing 
for the detection of measles-specific and rubella-spe-
cific IgM antibodies. Cameroon planned to introduce 
the (RCV) into the EPI in 2016 starting by a national 
measles and rubella mass vaccination campaign for 
children under 15 years. WHO recommends that epide-
miological analysis should be carried out in the process 
of rubella vaccine introduction to evaluate the burden 
of the disease.9 However, very limited studies have been 
conducted in the country to determine the epidemiology 
of the disease and gather baseline evidence prior to this 
introduction.
This study aims to determine the epidemiology of 
rubella disease in Cameroon based on the national 
measles case-based surveillance system from 2008 to 2014. 
The outcome of this analysis provides baseline data for 
future monitoring of the impact of rubella vaccines in the 
national EPI programme.
METHODS
Sampling and laboratory procedure
We carried out a cross-sectional study on the national 
rubella case-based surveillance activities for the period 
2008 to 2014 in Cameroon. Cameroon is located in 
Central Africa within the WHO African Region with a 
projected population of 22 179 707 habitants in 2015. It 
was estimated that children under 5 years account for 
about 16.6% and about 51% of the population were 
female.10 Life expectancy at birth is estimated to be 58 
years, and the total fertility rate is six children per woman 
of childbearing age.11
During the study period, blood samples were collected 
by nurses from persons with rash and fever within 14 days 
of onset of rash according to the standard WHO African 
Regional Office (WHO/AFRO) case definition for a 
suspected measles case (ie, any person with generalised 
maculopapular rash and fever plus one of the following: 
cough or coryza (runny nose) or conjunctivitis (red eyes) 
or any person in whom a clinician suspects measles). This 
case definition was applied to both children and adults 
seeking care in health facilities all over the country. 
According to the WHO guidelines for measles case 
confirmation, suspected cases were tested for the pres-
ence of measles IgM antibodies.12 However, in the case 
of a measles outbreak, only five suspected cases are 
tested for the presence of measles IgM antibodies and 
if three or more of the cases test measles IgM positive, 
this is declared as a laboratory-confirmed outbreak. In 
the confirmed outbreak situation, no further samples are 
collected in the affected area until 30 days after the initial 
confirmation of the outbreak.
At first contact with a suspected measles case, about 
1–5 mL of blood was collected by venipuncture into 
a sterile anticoagulant-free tube. The blood was then 
allowed to clot then centrifuged at 3000 rpm for 5 min 
to separate the serum. If there was no centrifuge in the 
health centre, the blood was stored in a refrigerator until 
the clot was completely retracted from the serum. The 
serum was transferred aseptically into a phial and stored 
at 2°C–8°C for at most 3 days before being transported 
in a cold chain to Pasteur Institute Cameroon, which 
houses the national measles/rubella surveillance labora-
tory, accredited by the WHO Global Measles and Rubella 
Laboratory Network (Labnet).
In the testing laboratory, sera were stored at −20°C 
and tested within 7 days. ELISA for rubella-specific IgM 
antibodies was carried out according to the manufac-
turer’s instructions (Enzygnost Anti-Rubella Virus/IgM 
kit; Siemens, Erlangen, Germany). Patients with rubella 
IgM-positive serum samples were classified as laborato-
ry-confirmed rubella cases. Due to limited resources, all 
samples were tested once and those producing equivocal 
results were not retested.
Data management and analysis
The laboratory results and completed individual case 
investigation forms were sent to the EPI programme. 
Forms collected from the laboratory were reviewed and 
entered into the WHO electronic database. The case-
based surveillance data were reported on a weekly basis 
by the EPI programme to the WHO country office.
Statistical analyses were performed using the SPSS 
statistical package (V.16). Data were cleaned and anal-
ysis of rubella cases done by year, age, age group, sex, 
setting/region and months. Descriptive analysis was 
completed with bivariate analyses using χ2 or Fisher’s 
exact tests for categorical variables to find key deter-
minant of rubella infection in Cameroon. A 95% CI 
was calculated for the OR, and values of p<0.05 were 
considered statistically significant. Logistic regression 
analysis was used to estimate OR of IgM seropositivity 
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as outcome variable with age, sex and setting as explan-
atory variable.
RESULTS
Proportion of rubella diseases
A total of 9907 samples from suspected measles cases 
were received in the laboratory from 2008 to 2014 among 
which 7489 (75.59%) measles-negative samples were 
tested for rubella; 699 (9.3%) were positive for rubella 
IgM antibodies. The proportion of rubella IgM antibodies 
varied from 4.7% in 2009 to 12.4% in 2012 (table 1). Also, 
results of 202 (2.7%) cases were indeterminate and were 
treated as negative.
Distribution of rubella cases by age
Among the 699 positive cases, the median age was 5 years, 
range 5 months to 68 years. Figure 1 shows that 2.43% 
of rubella-positive cases were children below 1 year of 
age (representing the targeted age in the routine EPI 
programme) and 96.85% of cases were below 15 years 
(marking the entrance to childbearing age for young 
girls).
Rubella distribution by age group
The proportion by age group shows that the age groups 
between 5–9 years and 10–14 years had highest propor-
tions of rubella infection (figure 1 and table 2).
Distribution of rubella cases by sex
The sex was available for 698 cases (99.85%) out of 699. 
More than half (380/698, 54.44%) of positive rubella 
cases were females. Females were 1.3 times more asso-
ciated to a positive rubella IgM than males (OR 1.33; 
95% CI 1.14 to 1.56; p=0.0001) (table 2).
Rubella in women of childbearing age (15–49 years)
There were 242 females of childbearing age who were 
tested, 11 (4.55%) were positive for rubella IgM anti-
bodies. The proportion of positive rubella cases within 
this high-risk group varied from one year to another, with 
the lowest of 0.0% in 2008 and the highest of 15.8% in 
2012.
Rubella case distribution by setting/region
The setting was specified for 7466 suspected rubella cases 
(99.7%) out of 7489. There was no statistically signifi-
cant difference in proportion of rubella cases between 
urban and rural populations (OR 1.11; 95% CI 0.94 to 
1.31; p=0.208) (table 2). The proportion of rubella-pos-
itive cases by regions in Cameroon between 2008 and 
2014 shows that, the East, North-West and the South-
West regions had higher proportions of rubella cases 
(figure 2).
Table 1 Proportion of rubella cases in Cameroon by year 
(2008–2014)
Year
 Number tested 
for rubella IgM
Outcome of tests
Positive (%) Indeterminate (%)
2008 646 78 (12.1%) 20 (3.1%)
2009 688 32 (4.7%) 1 (0.1%)
2010 655 42 (6.4%) 6 (0.9%)
2011 1107 105 (9.5%) 30 (2.7%)
2012 1185 147 (12.4%) 43 (3.6%)
2013 1342 147 (11.0%) 44 (3.3%)
2014 1866 148 (7.9%) 58 (3.1%)
Total 7489 699 (9.3%) 202 (2.7%)
Figure 1 Rubella case distribution by age in Cameroon, 2008–2014.
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Seasonal distribution of rubella cases from 2008 to 2014
The analysis of the number of rubella cases during the 
study period 2008 to 2014 revealed an apparent season-
ality in Cameroon. Monthly variation showed that the 
number of rubella cases during the months of February 
to April was highest, which represents the end of the dry 
season and beginning of the raining season in most parts 
of Cameroon with a sharp decline in numbers in the 
months of July through September (figure 3).
Logistic regression analysis
Logistic regression analysis reveals associations of rubella 
IgM seropositivity with age. Compared with children 
less than 1 year of age, the association increased with 
age from 1 to 4 years (OR 7.11; 95% CI 4.35 to 12.41; 
p<0.0001), through 5 to 9 years (OR 13.07; 95% CI 7.93 
to 22.93; p<0.001), to 10 to 14 years of age (OR 13.86; 
95% CI 8.06 to 25.12; p<0.001). In addition, people aged 
15 years and above captured in the measles case-based 
surveillance system were also more likely to have rubella 
infection than children under one (OR 3.69; 95% CI 
1.85 to 7.48; p=0.0001). There were also significant asso-
ciations with sex, with males being less associated to a 
positive rubella IgM than females (OR 1.33; 95% CI 1.14 
to 1.56; p=0.0001).
DISCUSSION
The national measles case-based surveillance system in 
Cameroon enabled the estimation of the proportion of 
rubella infections among suspected measles cases. From 
this study, we observed that during the measles outbreaks 
between 2008 and 2014, the proportion of rubella cases 
ranged from 4.7% in 2009 to 12.4% in 2012, with number 
of cases ranging from 32 to 148 per year. The increase in 
the proportion of rubella cases during this period could 
Table 2 Distribution of rubella cases by some sociodemographic characteristics in Cameroon, 2008–2014
Number tested for rubella Number tested positive (%) OR 95% CI P value
Age group
  <1 year 1244 17 (1.37) 1 0.0001
  1–4 years 3635 326 (8.97) 7.11 4.35 to 12.41
  5–9 years 1610 247 (15.34) 13.07 7.93 to 22.93
  10–14 years 540 87 (16.11) 13.86 8.06 to 25.12
  ≥15 years 452 22 (4.87) 3.69 1.85 to 7.48
  Total 7481 699 (9.3)
Sex
  Male 3904 318 (8.2) 1 0.0001
  Female 3584 380 (10.6) 1.33 1.14 to 1.56
  Total 7488 698 (9.3)
Setting
  Rural 4815 435 (9.0) 1 0.208
  Urban 2651 264 (9.9) 1.11 0.94 to 1.31
  Total 7466 699 (9.3)
Figure 2 Distribution of rubella-positive cases by region in Cameroon, 2008–2014.
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actually be indicating a rubella outbreak also, and this 
type of observation necessitates a clear case definition of 
rubella infection. Also, the observed increase in rubella 
cases detected, particularly in 2010 and 2011, could be 
attributed to the improvements in the sensitivity of the 
measles case-based surveillance system, through linkage 
with the strengthened acute flaccid paralysis surveillance 
system within the context of polio eradication.
Most rubella cases were reported in children below 
15 years, indicating that rubella was mainly an illness of 
young and early-school-age children. This was similar to 
findings in Ethiopia and Zimbabwe where 94% and 98% 
of cases, respectively, came from this age group.13 14 Simi-
larly, the lowest proportion of cases was seen in children 
below 1 year thereby substantiating the potential benefit if 
a rubella vaccine is incorporated into the national routine 
immunisation programme which targets children of this 
age group. Vaccinating children in the routine immu-
nisation programme at this age will provide protection 
against rubella in these children through adolescence 
and adulthood by interrupting virus circulation early in 
childhood and ideally establishing herd immunity in the 
population. This will further reduce the risk of acquiring 
rubella infection during pregnancy and also reduce the 
burden of CRS.
The proportion of females of reproductive age with 
positive rubella IgM among captured suspected measles 
cases was very low (4.55%). It has been documented in 
other regions that, higher rubella IgM seroprevalence 
rate was observed in children and adolescent than in 
adults, with the trend of IgM positivity decreasing with 
increase in age.13 15–20 The apparent association of posi-
tive rubella IgM results to females should be interpreted 
with caution as the small differences could be as a result 
of diagnostic or selection bias in the women than in the 
men.
There was an apparent seasonal trend in the number of 
rubella cases where peaks were seen during the end of the 
dry season (February) and beginning of the raining season 
(April) in most parts of Cameroon with a sharp decline 
in numbers in the month of July through September 
then gradually begins to increase from October through 
December. A similar trend was noted by Mitiku et al13 in 
Ethiopia where a seasonal distribution of cases occurred 
each year and peaked from March to June. Rubella cases 
in this study do not show any statistically significant differ-
ence between urban and rural populations. Mitiku et al13 
noted a significantly higher number of positive cases in 
the urban areas compared with rural areas.
Occurrence of rubella antibodies in children of 5 
months in this study indicates possibility of infection at 
a younger age although CRS burden is still unknown in 
Cameroon. In a literature review of CRS and acquired 
rubella in developing countries, Cutts et al reported that 
data from developing countries suggested that the risk of 
CRS is at least as high as that in industrialised countries 
during the prevaccination era.21 The incidence of CRS 
per 1000 live births in Cameroon is still unknown. Jivraj 
et al22 revealed ocular and auditory manifestations of CRS 
among 320 students from two schools (one for children 
with hearing impairment and one for children with normal 
hearing) in Mbingo, Cameroon with 28 (10.2%) prob-
able or clinically confirmed cases according to the WHO 
case definitions. A probable case of CRS was defined as an 
individual with two or more of the following conditions: 
cataract, congenital glaucoma, pigmentary retinopathy 
or hearing impairment which are clinical major signs of 
rubella infection. Hearing-impaired children were seven 
times more likely to have positive serology (48.8%) than 
children with normal hearing (7.4%; p<0.0001).22
These results are subject to some limitations. First, 
the case definition used to detect the rubella cases was 
designed for the measles case-based surveillance system. 
Many individuals with rubella disease may not have 
rash which occurs in 50%–80% of persons infected 
with rubella.9 The sensitivity of the case definition used 
for measles surveillance is likely not high enough to 
identify all rubella cases. The system also relies mostly on 
health facilities and may have missed some community 
cases. The database also shows existence of missing data 
for some variables highlighting some issues in the data 
management and rapid control applications for some key 
variables.
However, the integration of rubella testing with measles 
case-based surveillance provides an opportunity to gain 
understanding about the epidemiology of rubella infec-
tion. To better understand the burden and epidemiology 
of rubella and CRS, Cameroon may consider integration 
of both surveillances by adopting a more inclusive case 
definition for measles and rubella, and also conducting 
well-designed population base studies on rubella burden. 
The following definition was used by the Pan American 
Health Organization for rubella surveillance as the region 
moved towards an elimination target: a suspected case 
is one in which a health worker suspects rubella.23 The 
European Centre for Disease Prevention and Control also 
adopted a modified definition, namely, any person with 
sudden onset of generalised maculopapular rash and at 
Figure 3 Monthly trends in the number of samples testing 
positive for rubella in Cameroon, 2008–2014.
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least one of the following: cervical adenopathy, suboc-
cipital adenopathy, postauricular adenopathy, arthralgia 
or arthritis.24 As Cameroon and other African countries 
work toward introducing RCVs and plan elimination 
goals, a modified case definition will need to be consid-
ered so as to improve detection rates.
Another major issue Cameroon should consider when 
introducing rubella vaccination is that a high vaccination 
coverage above 80% is required to sustain immunity from 
childhood to older age groups. A coverage below 80% in 
children will mean shifting susceptibility to rubella in a 
good number of unvaccinated children through older 
age particularly in women of childbearing age, thereby 
secondarily incrlinkedeasing the risk of CRS. Such a shift 
in susceptibility to older age groups occurred and was 
documented in Greece and South Africa.25 26
Cameroon should therefore consider establishing a 
sentinel surveillance for CRS and find additional strate-
gies to fill immunity gaps in older age groups. Information 
from such studies will be useful in monitoring the impact 
of introducing a rubella vaccine into the EPI programme.
CONCLUSION
Rubella virus circulates in Cameroon with an important 
number of children under 15 years being affected. 
Children under 1 year presented with low propor-
tions indicating a potential benefit of introducing a 
rubella vaccine into the national routine immunisation 
programme, as this will mean a good opportunity to inter-
rupt virus circulation and protect many children through 
adolescence and adulthood.
To better understand the burden and epidemiology of 
rubella and CRS, Cameroon should consider including 
a more inclusive case definition for measles and rubella, 
establishing sentinel surveillance for CRS and conducting 
appropriate postvaccine studies once the vaccine is 
introduced into the national immunisation programme 
among high-risk susceptible groups of the popula-
tion. Information from such studies will be useful for 
rubella elimination strategies in Cameroon.
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